Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
JERSEY, Channel Islands, March 01, 2018 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Paul Cowan, will present at the Cowen 38th Annual Global Health Care Conference on Tuesday, March 13th, 2018 at 8:00 a.m. EDT at The Boston Marriott Copley Place, in Boston, MA. The Company's Chief Financial Officer, Chris Lindop, will also be participating in the conference.
A webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.quotientbd.com. A webcast replay will be archived on the website for approximately 90 days.
About Quotient Limited
Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and serological disease screening, Quotient is developing its proprietary MosaiQ™ technology platform to offer a breadth of tests that is unmatched by existing commercially available transfusion diagnostic instrument platforms. The company's operations are based in Edinburgh, Scotland; Eysins, Switzerland and Newtown, Pennsylvania.
The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.
CONTACT: Chris Lindop, Chief Financial Officer — [email protected]; +41 (0)799 61 69 38
